Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · Real-Time Price · USD

0.00

+0.118 (1.00%)

Apr 29, 2026, 9:36 AM EDT - Market open

Kazia Therapeutics Employees

Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.

Employees

6

Change (1Y)

-1

Growth (1Y)

-11.76%

Revenue / Employee

$211,072

Profits / Employee

-$2,534,761

Market Cap

135.41M

Employees Chart

Employees History

Date	Employees	Change	Growth
Jun 30, 2025	6	-1	-11.76%
Jun 30, 2024	7	-	-

Related Stocks

Company Name	Employees
Innate Pharma	174
Fate Therapeutics	161
Immunic	92
Verrica Pharmaceuticals	76
Tenaya Therapeutics	70
Connect Biopharma Holdings	64
Biomea Fusion	41
Equillium	35

Employee Rankings

KZIA News

14 days ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
15 days ago - Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - PRNewsWire
3 months ago - Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) - PRNewsWire
3 months ago - Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - PRNewsWire
3 months ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
4 months ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
5 months ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
5 months ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga